Tecentriq (Atezolizumab) Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Tecentriq (Atezolizumab) market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period can be attributed to the increased demand for minimal residual disease (MRD) monitoring, the importance of real-world evidence, rising interest in novel drug formulations, high rates of triple-negative breast cancer, and the growing use in first-line treatment settings.

Factors driving growth in the forecast period include an increasing focus on early detection and prevention, growing cancer survival rates, expanding global cancer research initiatives, higher healthcare spending in developing economies, and increased awareness among patients and physicians. Key trends in the forecast period include the integration of artificial intelligence (AI), telemedicine and remote monitoring, regulatory innovations, advancements in biomarker discovery, and innovative drug development.

The increasing prevalence of cancer is expected to drive the growth of the tecentriq (atezolizumab) market. This rise in cancer cases can be attributed to factors such as an aging population, better detection techniques, lifestyle changes, environmental exposures, and improved survival rates, all contributing to more people being diagnosed and living with cancer. Tecentriq (atezolizumab) is vital for cancer treatment as it utilizes the immune system to combat cancer by blocking PD-L1, a protein that allows tumors to evade immune detection. This enables the immune system's T-cells to recognize and destroy cancer cells more effectively. For example, in January 2024, the American Cancer Society reported a rise in cancer cases, with the number of new cases increasing to 2,001,140 from 1,958,310 in 2023, a growth of 2.19%. As a result, the growing prevalence of cancer is driving the tecentriq (atezolizumab) market forward.

A key trend in the tecentriq (atezolizumab) market is the development of innovative products, such as intravenous formulations of atezolizumab, aimed at ensuring precise dosing, rapid systemic absorption, and consistent therapeutic levels. The intravenous formulation is a liquid preparation administered directly into the bloodstream via infusion, designed to efficiently deliver the monoclonal antibody for systemic cancer treatment. For example, in September 2024, Genentech Inc. received approval from the U.S. Food and Drug Administration for atezolizumab and hyaluronidase-tqjs for subcutaneous injection. Tecentriq, the first subcutaneous anti-PD-L1 therapy approved in the U.S., offers a distinct advantage with a faster administration time of approximately 7 minutes compared to the 30-60 minutes required for intravenous infusion, while maintaining comparable efficacy in drug exposure and overall response rates, as demonstrated in the IMscin001 trial. It is approved for various adult cancers, including NSCLC, SCLC, melanoma, hepatocellular carcinoma, and alveolar soft part sarcoma.

In October 2024, Lonza Group AG, a Switzerland-based pharmaceutical, biotechnology, and nutrition company, acquired Roche's Vacaville large-scale biologics manufacturing facility for $1.2 billion. This acquisition establishes a strong West Coast manufacturing presence near the San Francisco biotech hub, complementing Lonza’s existing East Coast site in Portsmouth, New Hampshire, and its global network in Europe and Asia Pacific. The expansion significantly strengthens Lonza's ability to manufacture late-stage clinical and commercial products and support the production of new molecules approaching commercialization. Roche Holding AG, a Switzerland-based manufacturer of pharmaceuticals and biologics, produces Tecentriq (atezolizumab).

Major players operating in the tecentriq (atezolizumab) market are Roche Holding AG, and Chugai Pharmaceutical Co. Ltd.

North America was the largest region in the tecentriq (atezolizumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in tecentriq (atezolizumab) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the tecentriq (atezolizumab) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tecentriq (atezolizumab) is a monoclonal antibody-based immunotherapy that belongs to a class of cancer treatments called immune checkpoint inhibitors. It specifically targets the protein programmed death ligand 1 (PD-L1), blocking the interaction between PD-L1 (found on tumor and immune cells) and PD-1 or B7.1 receptors on T-cells. This inhibition reactivates the immune system, allowing T-cells to recognize and destroy cancer cells.

The primary types of tecentriq (atezolizumab) include PD-L1 inhibitors, PD-1 inhibitors, CTLA-4 inhibitors, immunomodulators, and others. Tecentriq PD-L1 Inhibitor is a monoclonal antibody that blocks PD-L1, a protein that suppresses the immune response against cancer cells. It is used for treating lung cancer, bladder cancer, melanoma, Hodgkin's lymphoma, head and neck cancer, and others. Tecentriq is distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies, and is used by different end users such as hospitals, home care providers, specialty clinics, and others.

The tecentriq (atezolizumab) market research report is one of a series of new reports that provides tecentriq (atezolizumab) market statistics, including tecentriq (atezolizumab) industry global market size, regional shares, competitors with a tecentriq (atezolizumab) market share, detailed tecentriq (atezolizumab) market segments, market trends and opportunities, and any further data you may need to thrive in the tecentriq (atezolizumab) industry. This tecentriq (atezolizumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The tecentriq (atezolizumab) market consists of sales of biosimilars, immuno-oncology pipeline drugs, supportive oncology medications and related products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.